#160: Statins and diabetes risk: More data; clopidogrel poststenting: The case for shorter duration, interruptions; EMA supports apixaban for AF/stroke; statins do not reduce the risk of VTE: New meta-analysis; rethinking routine testing of chest-pain pat
Statins and diabetes risk: More data; clopidogrel poststenting: The case for shorter duration, interruptions; EMA supports apixaban for AF/stroke; statins do not reduce the risk of VTE: New meta-analysis; rethinking routine testing of chest-pain patients
Source: Radio TheHeart.org - Category: Cardiology Authors: theheart.org Tags: This week in cardiology from heartwire Source Type: podcasts
More News: Cardiology | Cholesterol | Clopidogrel | Diabetes | Endocrinology | Heart | Pain | Plavix | Statin Therapy | Stroke